Impressive results from Zogenix Inc.'s first Phase III study of ZX008 (low-dose fenfluramine) in the life-threatening epilepsy condition Dravet syndrome are holding up well so far in comparison to the leading drug in the development space – GW Pharmaceuticals PLC 's Epidolex (cannabidiol, or CBD) – and may support an earlier filing than expected.
In a top-line release on Sept
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?